Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve Patients with Advanced or Metastatic Non-Clear Cell RCC By Ogkologos - April 15, 2025 455 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUNNIFORECAST study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof... March 23, 2026 FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer January 17, 2025 Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment... April 27, 2026 How do we die of cancer? What we know (and what... May 8, 2022 Load more HOT NEWS Magnetic Fish-Shaped Microbots Deliver Chemotherapy to Exactly Where It’s Needed Tucatinib and Trastuzumab Combination Approved for Advanced Colorectal Cancer Using Integrative Therapies to Help Manage Cancer-Related Pain: An Expert Q&A The Timing for the Age of which Natural Menopause Occurs
